avacopan + prednisolone + rituximab

This is a combination therapy consisting of three agents used in the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, particularly granulomatosis with polyangiitis and microscopic polyangiitis. **Avacopan** is an oral small molecule that acts as a selective antagonist of the complement component 5a receptor 1 (C5aR1), thereby inhibiting C5a-mediated neutrophil activation and migration, which are key drivers in ANCA-associated vasculitis. **Prednisolone** is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressive properties, commonly used to control acute inflammation in autoimmune diseases. **Rituximab** is a monoclonal antibody targeting B lymphocyte antigen CD20, leading to B cell depletion; it plays a central role in both induction and maintenance of remission for ANCA-associated vasculitis. Clinical studies have shown that combining these agents—especially using avacopan with rituximab—can induce and sustain remission while reducing glucocorticoid exposure and associated toxicity[1][3][4][6]. Avacopan has demonstrated noninferiority or superiority to prednisone taper regimens for sustained remission at 52 weeks when combined with background induction therapy such as rituximab[3][4][6]. This regimen offers improved renal outcomes, lower relapse rates, faster reduction in albuminuria, and reduced glucocorticoid toxicity compared to traditional high-dose steroid approaches[4][6].

Other names

CCX168CCX-168CCX 168TAVNEOSRTX